Swiss pharma giant Roche is the latest company to refocus its R&D investment on diseases like obesity that weigh heavily on healthcare budgets. This comes as governments increasingly demand drugs that save not only lives but also money. The blockbuster drugs Ozempic and Wegovy have shown there is a goldmine waiting for pharma companies that can develop treatments for mass-market diseases such as obesity and diabetes. Novo Nordisk, the Danish group behind the drugs, has seen its share price surge to record highs this year, making it the most valuable company in Europe with a market capitalisation of over $530 billion (CHF457 billion). The success of these wonder drugs has injected new energy into the hunt not only for the next-generation weight-loss hit, but for other drugs that can create similar dramatic changes in the treatment of major diseases that affect millions of people worldwide. Basel-based Roche is the latest pharma giant to announce a revamp of its investment strategy …